Immunotherapy combo may boost liver cancer surgery success
NCT ID NCT04658147
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This early-stage study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before and after surgery is safe and helps patients with liver cancer that can be removed. About 31 adults with resectable liver cancer will receive the drugs, then undergo surgery. The main goal is to see how many patients can complete the pre-surgery treatment and proceed to surgery, while also checking for side effects and how well the tumor is removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
The Ohio State University, Wexner Medical Center
Columbus, Ohio, 43210-1002, United States
Conditions
Explore the condition pages connected to this study.